Skip to main content
    B

    Biogen Inc (BIIB)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $251.65
    -1.75 (-0.69%)

    Market Cap: $37.46B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Biogen Inc (BIIB) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Biogen (BIIB) to earn $12.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $10.57B. Of 36 analysts, 25 rate the stock Buy or Strong Buy, 10 Hold and 1 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $16.26.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 36 ratings average 2.22, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 69% of the ratings.

    RatingAnalystsShare
    Strong Buy411.1%
    Buy2158.3%
    Hold1027.8%
    Sell12.8%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    36

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 29.8% and revenue estimates rise 2.0%.

    Fiscal year ending Dec 31, 2026
    $12.53
    EPS consensus, revenue $10.57B
    Fiscal year ending Dec 31, 2027
    $16.26
    EPS consensus, revenue $10.78B
    Next report
    Feb 4, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$12.53$12.22 to $13.0733$10.57B$10.28B to $11.40B34
    Dec 31, 2027$16.26$13.90 to $18.6735$10.78B$10.21B to $11.09B34

    Quarterly Estimates

    The EPS consensus rises from $2.81 for the quarter ending Dec 31, 2026 to $3.57 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.81$2.39 to $3.4533$2.65B$2.38B to $3.55B32
    Mar 31, 2027$3.57$2.93 to $4.1813$2.61B$2.37B to $2.73B12

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 20271212

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.7% from $12.44.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$12.53$12.53$12.43$12.49$12.44+0.7%
    Fiscal year ending Dec 31, 2027$16.26$16.28$16.55$16.55$16.60-2.1%
    Quarter ending Mar 31, 2027$3.57$3.55$3.65$3.65$3.65-2.2%

    Frequently Asked Questions About BIIB

    What is the BIIB stock forecast?

    Consensus analyst estimates put Biogen's EPS at $12.53 for the fiscal year ending Dec 31, 2026, on revenue of $10.57B. The consensus rating from 36 analysts is Buy.

    How do analysts rate BIIB stock?

    Of 36 analysts covering Biogen, 4 rate it Strong Buy, 21 Buy, 10 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from BIIB next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $12.53, with estimates from $12.22 to $13.07 from 33 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $16.26, with estimates from $13.90 to $18.67 from 35 analysts.

    What revenue do analysts expect from Biogen next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $10.57B, with estimates from $10.28B to $11.40B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $10.78B, with estimates from $10.21B to $11.09B.

    How many analysts cover BIIB?

    36 analysts rate Biogen stock, and 33 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.